trending Market Intelligence /marketintelligence/en/news-insights/trending/vw6DKG-7Kf7mxlH84Wa4dw2 content esgSubNav
In This List

Ampio's knee osteoarthritis injection effective in phase 3 trial


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Ampio's knee osteoarthritis injection effective in phase 3 trial

Ampio Pharmaceuticals, Inc.'s knee osteoarthritis injection Ampion met its primary goal in a phase 3 trial with 71% of patients reporting improvement in pain, function and quality of life.

Osteoarthritis is an incurable and progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments and bone.

The patient response in the trial exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee.

On average, patients saw a 53% decrease in pain, 50% improvement in function and a 45% improvement in quality of life.

If approved, Ampion would be the first intra-articular injection to treat osteoarthritis of the knee. Ampion is also a non-opioid treatment.

The company is preparing to submit a biologics license application to the U.S. Food and Drug Administration.